Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study

• Published in: Ophthalmology and therapy 2024-01, Vol.13 (1), p.161-178
• Main Authors: Donati, Simone, Yang, Chang-Hao, Xu, Xun, Mura, Marco, Giocanti-Aurégan, Audrey, Hoerauf, Hans, Allmeier, Helmut, Machewitz, Tobias, Johnson, Kristian T., Santoro, Elina
• Format: Article
• Language: English
• Subjects: Anti-vascular endothelial growth factor; Diabetes; Diabetic macular edema; Diabetic retinopathy; Internal Medicine; Intravitreal aflibercept; Medicine; Medicine & Public Health; Observational study; Ophthalmology; Original Research
• ISSN: 2193-8245; 2193-6528
• DOI: 10.1007/s40123-023-00829-3

Introduction AURIGA is the largest real-world study to date to evaluate intravitreal aflibercept (IVT-AFL) in the treatment of diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion in routine clinical practice. The 24-month outcomes in the DME cohort from across 11 participating countries are reported here. Methods AURIGA (NCT03161912) was a prospective observational study. The study enrolled eligible patients with DME for whom the decision to treat with IVT-AFL had previously been made by the attending physician. Patients were treated with IVT-AFL for up to 24 months at physician discretion according to local practice. The primary endpoint was mean change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from baseline to month 12 (M12). All statistical analyses were descriptive. Results In 1478 treatment-naïve and 384 previously treated patients with DME, the mean (95% confidence interval) change in VA from baseline was +6.7 (5.7, 7.6) and +7.4 (5.5, 9.4) letters by M12 and +5.9 (4.9, 6.9) and +8.1 (6.1, 10.1) letters by M24 (baseline [mean ± standard deviation]: 56.0 ± 19.8 and 50.8 ± 19.5 letters), respectively; 25.9% of treatment-naïve and 32.8% of previously treated patients achieved ≥ 15-letter gains by M24. The mean change in central retinal thickness from baseline to M24 was −110 (−119, −102) µm in treatment-naïve patients and −169 (−188, −151) µm in previously treated patients. By M6, M12, and M24, treatment-naïve patients had received 3.8 ± 1.7, 4.9 ± 2.8, and 5.7 ± 3.9 injections, respectively, and previously treated patients had received 3.9 ± 1.5, 4.9 ± 2.4, and 6.2 ± 3.6 injections, respectively. The safety profile of IVT-AFL was consistent with previous studies. Conclusion In AURIGA, treatment-naïve and previously treated patients with DME achieved clinically relevant functional and anatomic improvements following IVT-AFL treatment for up to 24 months in routine clinical practice. Even with the decreasing injection frequency observed, these gains were largely maintained throughout the study, suggesting long-term durability of the positive effects of IVT-AFL treatment. Infographic available for this article. Trial Registration ClinicalTrials.gov Identifier: NCT03161912 (May 19, 2017). Infographic